Review

Rev Diabet Stud, 2011, 8(3):392-402

DOI 10.1900/RDS.2011.8.392

The Kidney in Type 2 Diabetes Therapy

Hiddo J. Lambers Heerspink¹, Dick de Zeeuw²

¹Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Netherlands
²Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, the Netherlands
Address correspondence to: Hiddo J. Lambers Heerspink, e-mail: h.j.lambers.heerspink@umcg.nl

Manuscript submitted October 10, 2011; resubmitted October 29, 2011; accepted November 1, 2011.

Keywords: ACE-inhibitor, albuminuria, angiotensin receptor blockade, endothelin, inflammation, nephropathy, novel drug, type 2 diabetes, vitamin D

Abstract

Renal and cardiovascular complications make type 2 diabetes one of the most morbid conditions in medicine. The kidney frequently gets involved in this "multi-organ disease". Of the large proportion of patients who progress with further loss of renal function, most prematurely die or end up in dialysis. Many interventions have targeted a decelerated progression of renal function loss, including metabolic control, blood pressure, and lipid management. Recently, modulation of the renin-angiotensin-aldosterone-system (RAAS) have been combined with the existing therapeutic armamentarium. RAAS inhibitors lower blood pressure and decrease albuminuria which leads to additionally protective renal and cardiovascular effects. Although this has been the success story of the last two decades, it has still made a relatively small contribution to patient welfare, since the residual risk in patients that received this optimal care remains extremely high. New treatment strategies are required that further slow the progression of renal and cardiovascular functions. Recently, several pathways have been investigated, targeting traditional risk factors such as blood pressure- and lipid-lowering strategies with unexpected results. Furthermore, novel targets and drugs have been identified. Preliminary studies on surrogate markers for renal outcome show a great potential for additive renal protection, such that in many cases hard endpoint trials are initiated. Novel interventions, which are reviewed here, include vitamin D receptor activators, RAASi with direct renin inhibitors or aldosterone antagonists, endothelin-antagonist, inflammation suppression with pentoxyfillin, MCP-1 synthesis inhibitors, or with Nrf2 agonists. Despite the current depressing situation of type 2 diabetic patients with nephropathy, new treatment options are under development to reduce the high morbidity and mortality associated with this universal ever-increasing disease threat.

Fulltext: HTML , PDF (176KB)

This article has been cited by other articles:

	Are post-trial observational studies useful? Heerspink HJ, de Zeeuw D J Am Soc Nephrol 2014. 25(10):2148-2150

	Saturated fatty acids and type 2 diabetes: more evidence to re-invent dietary guidelines Mozaffarian D Lancet Diabetes Endocrinol 2014. 2(10):770-772

	Do diabetic kidneys deserve a lifestyle change? de Zeeuw D1, Lambers Heerspink H2. Lancet Diabetes Endocrinol 2014. 2(10):769-770

	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH J Am Soc Nephrol 2014. 25(5):1083-1093

	Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice Pei F, Li BY, Zhang Z, Yu F, Li XL, Lu WD, Cai Q, Gao HQ, Shen L J Diabetes Complications 2014. 28(5):596-603

	Multiple low-dose radiation prevents type 2 diabetes-induced renal damage through attenuation of dyslipidemia and insulin resistance and subsequent renal inflammation and oxidative stress Shao M, Lu X, Cong W, Xing X, Tan Y, Li Y, Li X, Jin L, Wang X, Dong J, Jin S, Zhang C, Cai L Plos One 2014. 9(3):e92574

	Clinical challenges in diagnosis and management of diabetic kidney disease Stanton RC Am J Kidney Dis 2014. 63(2 Suppl 2):S3-S21

	Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system Matsumoto T, Lopes RA, Taguchi K, Kobayashi T, Tostes RC Life Sci 2014. 118(2):129-135

	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Muskiet MH, Smits MM, Morsink LM, Diamant M Nat Rev Nephrol 2014. 10(2):88-103

	Effects of combinations of Xiexin decoction constituents on diabetic nephropathy in rats Wu JS, Liu Y, Shi R, Lu X, Ma YM, Cheng NN J Ethnopharmacol 2014. 157:126-33

	Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM, BEACON Trial Investigators N Engl J Med 2013. 369(26):2492-2503

	Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension) Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H Hypertens Res 2013. 36(12):1051-1059

	Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D Nephrol Dial Transplant 2013. 28(11):2841-2850

	Why is organ transplantation clinically important? Grinyo JM Cold Spring Harb Perspect Med 2013. 3(6):a014985

	Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON) de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM Am J Nephrol 2013. 37(3):212-222

	AQP4 KO exacerbating renal dysfunction is mediated by endoplasmic reticulum stress and p66Shc and is attenuated by apocynin and endothelin antagonist CPU0213 Cheng YS, Dai DZ, Dai Y Eur J Pharmacol 2013. 721(1-3):249-258

	Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats Castoldi G, di Gioia CR, Bombardi C, Preziuso C, Leopizzi M, Maestroni S, Corradi B, Zerbini G, Stella A Am J Nephrol 2013. 37(1):65-73

	Obesity and diabetic kidney disease Maric-Bilkan C Med Clin North Am 2013. 97(1):59-74

	Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target Zenkov NK, Menshchikova EB, Tkachev VO Biochemistry (Mosc) 2013. 78(1):19-36

	Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats Wu JS, Shi R, Zhong J, Lu X, Ma BL, Wang TM, Zan B, Ma YM, Cheng NN, Qiu FR Evid Based Complement Alternat Med 2013. 2013:715671

	Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy Gu HF, Ma J, Gu KT, Brismar K Front Endocrinol (Lausanne) 2013. 3:179

	Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, Watanabe S, Baba O, Kojima Y, Shizuta S, Imai M, Tamura T, Kita T, Kimura T Circ Cardiovasc Genet 2011. 4(4):446-454

	The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS Special Issue Raz I, Gallwitz B Rev Diabet Stud 2011. 8(3):288-292

Internal Link

The Kidney in Type 2 Diabetes Therapy (176KB)

Special Issue

Drug Development and Clinical Trials in Type 2 Diabetes and its Complications

Edited by:
Baptist Gallwitz and Itamar Raz

Issue-Based Impact Factor:
2013: 4.333
2014: 6.417

[More]